Analyst Price Targets — INSM
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 24, 2026 11:49 am | — | Mizuho Securities | $204.00 | $159.03 | TheFly | Insmed price target lowered to $204 from $211 at Mizuho |
| February 20, 2026 1:15 pm | — | Morgan Stanley | $166.00 | $158.80 | TheFly | Insmed price target raised to $166 from $162 at Morgan Stanley |
| February 20, 2026 11:27 am | Tiago Fauth | Wells Fargo | $208.00 | $161.00 | TheFly | Insmed price target lowered to $208 from $234 at Wells Fargo |
| February 19, 2026 6:38 pm | — | Stifel Nicolaus | $205.00 | $159.88 | TheFly | Insmed price target lowered to $205 from $212 at Stifel |
| February 19, 2026 12:18 pm | Graig Suvannavejh | Mizuho Securities | $211.00 | $151.11 | TheFly | Insmed price target lowered to $211 from $212 at Mizuho |
| January 27, 2026 9:24 pm | Eliana Merle | Barclays | $231.00 | $162.64 | TheFly | Insmed initiated with an Overweight at Barclays |
| January 22, 2026 9:10 pm | — | Roth Capital | $212.00 | $160.39 | TheFly | Insmed initiated with a Buy at Roth Capital |
| January 21, 2026 11:35 am | Leonid Timashev | RBC Capital | $200.00 | $163.51 | TheFly | Insmed price target raised to $200 from $197 at RBC Capital |
| January 12, 2026 2:33 pm | Danielle Brill | Truist Financial | $205.00 | $166.26 | StreetInsider | Truist on Insmed (INSM): Brinsupri Launch Outpacing Most Bullish Expectations |
| January 8, 2026 12:46 pm | Maxwell Skor | Morgan Stanley | $157.00 | $176.00 | TheFly | Insmed price target lowered to $157 from $158 at Morgan Stanley |
Latest News for INSM
Eli Lilly and Company's shares rose during the quarter as Zepbound's obesity launch continued to gain strong traction. Cidara Therapeutics' shares rose further following Merck's acquisition of the company in a $9.2 billion all-cash deal announced in November 2025, representing a premium of more than 100% over the prior closing price. Doximity's stock detracted from performance as the company issued disappointing…
Insmed Incorporated (INSM) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Artisan Partners Limited Partnership grew its position in shares of Insmed, Inc. (NASDAQ: INSM) by 49.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,937,683 shares of the biopharmaceutical company's stock after purchasing an additional 1,623,342 shares during the period. Insmed makes
The portfolio generated strong absolute returns in Q4 and 2025 but trailed the MSCI All Country World Small Mid Index over each period. Stock selection in health care was the strongest contributor to performance for both the quarter and year. Management highlighted strong demand for high-speed optical components supporting AI-driven data center growth, alongside improving margins.
Insmed, Inc. (NASDAQ: INSM - Get Free Report) CEO William Lewis sold 10,699 shares of the firm's stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $150.97, for a total transaction of $1,615,228.03. Following the transaction, the chief executive officer directly owned 301,185 shares in the
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for INSM.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.